NORTH AMERICA MALE INFERTILITY MARKET FORECAST 2023-2032

In 2021, approximately 2.4% of all babies born in the United States resulted from ART, representing a 19% increase in ART cycles compared to the previous year. With 89,208 live births resulting from ART in 2021, the impact of these technologies on the male infertility market is evident. The United States continues to grapple with a high prevalence of infertility, creating a favorable environment for market growth. As awareness and access to treatments increase, the male infertility market is expected to strengthen further in the United States during the forecast period.

The North America male infertility market segmentation includes the analysis by treatment and test type. Market by test type covers DNA fragmentation technique, microscopic examination, sperm agglutination, oxidative stress analysis, computer-assisted semen analysis, sperm penetration assay, and other test types.

Semen analysis, conducted through microscopic examination methods, remains the most preferred diagnostic test for male infertility. Research indicates that infertility affects approximately 15-20% of reproductive-age couples, highlighting the increasing demand for microscopic testing as the number of infertility patients rises. Micromanipulator systems are utilized to enhance the chances of fertilization and pregnancy by precisely treating individual eggs, sperm, or embryos on a microscopic scale. These systems are particularly valuable in cases where sperm quality is poor. 

Furthermore, technological advancements in microscopy are expanding the use of microscopes in semen analysis. Digital documentation of microscopic specimens has become simpler and more effective, aiding in accurate analysis and documentation. These factors are expected to drive market developments in the field of male infertility diagnostics during the forecast period.

On the other hand, sperm agglutination is a test that measures the percentage of sperm sticking together in a sample. The ability of sperm to swim freely through the cervix is important for fertility, making agglutination undesirable. The procedure involves collecting a semen specimen on a microscope slide, covering it with a coverslip, and examining it. Semen analysis is considered the gold standard diagnostic technique for diagnosing male infertility. 

Ascorbic acid insufficiency and genital tract infections are two known causes of sperm agglutination. Immune infertility can result from anti-sperm antibodies (ASA) in males, with risk factors including scrotal trauma or surgery. Determining the frequency of agglutination in patients with immunological infertility is crucial, and the Mixed Antibody Reaction (MAR) test can be used to detect the presence of anti-sperm antibodies that cause agglutination and impair sperm’s ability to reach and bind with the egg’s outer layer.

Prominent players in the North America male infertility market entail Aytu BioPharma, AdvaCare Pharma, Laboratory Corporation of America Holdings, etc.

Labcorp, or Laboratory Corporation of America Holdings, is a prominent life sciences company based in the United States. Since its merger in 1995, Labcorp has provided comprehensive clinical laboratory and drug development services through its Labcorp Drug Development (DD) and Labcorp Diagnostics (Dx) segments. The company conducts various clinical laboratory tests on tissue, blood, and other specimens and offers crucial diagnostic, monitoring, and treatment support to healthcare professionals, hospitals, and commercial clients. Labcorp operates globally, serving clients in over 100 countries, with its headquarters in North Carolina, United States.

One of its diagnostic services from Labcorp, Y Chromosome Microdeletion Analysis, aids in diagnosing male infertility by identifying Y microdeletions and providing prognostic information. This analysis helps establish a diagnosis and uncover the genetic basis behind laboratory results, assisting in managing male infertility cases.